Affordable Access

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Authors
Type
Published Article
Journal
Haematologica
0390-6078
Publisher
Ferrata Storti Foundation
Publication Date
Volume
89
Issue
5
Pages
520–527
Identifiers
PMID: 15136214
Source
Medline

Abstract

Side effects and toxic discontinuation rates were higher than in previous studies, probably because this is the first long-term prospective study of the feasibility and toxicity of anagrelide treatment. Nevertheless, anagrelide is a valuable alternative for treatment of thrombocythemia in myeloproliferative disorders for patients who tolerate the drug well.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F